Company Research Report: Texas Retina Associates
Company Overview
Name: Texas Retina Associates
Mission: "Where your vision is our mission." Texas Retina Associates is committed to providing world-class retina care with community-based caring, ensuring the best possible outcomes through personalized and compassionate service.
Founded: The company was founded in 1966 by Albert Vaiser, MD, with William Snyder, MD, joining in 1968.
Key People:
- Ashkan M. Abbey, MD — Director of Clinical Research, Dallas
- Robert C. Wang, MD — Director of Clinical Research, Plano
- Patrick D. Williams, MD — Director of Clinical Research, Fort Worth
- Wayne A. Solley, MD — Director of Clinical Research, Arlington
- Michel J. Shami, MD — Director of Clinical Research, Lubbock
Headquarters: 9600 N Central Expressway, Suite 100, Dallas, Texas 75231
Number of Employees: No information is available.
Revenue: No information is available.
Core Competency: Texas Retina Associates is known for being North Texas' largest and most experienced ophthalmology practice, specializing in medical and surgical management of retina and vitreous diseases. They are renowned for their innovative, comprehensive, and compassionate care.
Products and Services
Products/Services Offered:
- Diagnosis and treatment of retina conditions such as macular degeneration and diabetic retinopathy.
- Comprehensive eye exams, particularly focusing on age-related macular degeneration (AMD).
- Access to more than 100 national clinical trials over the past 20 years.
Product Descriptions and Key Features:
1. Ophthalmic Care: Comprehensive medical and surgical treatment for retinal ailments.
- Specializes in complex conditions like ocular cancer and uveitis.
- Provides breakthrough treatments and clinical trials.
2. Clinical Trials: Available trials in various categories, including Diabetic Macular Edema, Wet AMD, Dry AMD with Geographic Atrophy, Retinal Vein Occlusion, Choroidal Melanoma, and Uveitis.
- Provides patients access to cutting-edge treatments.
- Operates in Dallas, Arlington, Lubbock, Fort Worth, and Plano.
3. Research Initiatives: Engaged in various clinical and groundbreaking research studies.
- Facilitates patient-centric studies in collaboration with national bodies like the National Eye Institute.
Recent Developments
Recent Developments:
- Leadership and Recognition: Dr. Ashkan M. Abbey served as guest medical editor for the January/February 2025 issue of Retina Today.
- Clinical Trials: Opened 10 new clinical trials focusing on diabetes-related eye conditions, age-related macular degeneration, and retinal vein occlusion.
- Research Publications: Recent publication by Dr. Abbey and team on outcomes of Intravitreal Aflibercept for neovascular AMD.
New Product Launches:
- Incorporation of the EYE-TIE, Ollin and other clinical trials focusing on the latest treatments for retina-related conditions.
New Features Added to Existing Products:
- Rollout of advanced clinical trials with multi-center studies involving cutting-edge treatments and formulations like EYE201 and OLN234.
Partnerships:
- Strong partnerships for research and clinical efforts, including collaborations with pharmaceutical companies, and national and international research entities.
Contact Information
Phone: 1 (800) 695-6941
Fax: 1 (214) 739-5797
Email: No information is available.
Website: [keyhealthplans.com](keyhealthplans.com)
Address: 9600 N Central Expressway, Suite 100, Dallas, Texas 75231
End of Report.
